Inflammation-Focused Device Maker Tivic Health Systems Sets Terms for $15 Million IPO

September 2021

September 9, 2021 -  Tivic Health Systems, which makes a non-invasive neuromodulation device for sinus and nasal inflammation, announced terms for its IPO on Thursday.

The Newark, CA-based company plans to raise $15 million by offering 2.7 million shares at a price range of $5 to $6. At the midpoint of the proposed range, Tivic Health Systems would command a fully diluted market value of $51 million.

Tivic is a commercial-phase bioelectronic medicine company focused on inflammation. Its first product, ClearUP Sinus Relief, is a patented handheld device that uses ultra-low current electrical waves to relieve symptoms of sinus and nasal inflammation. ClearUP is a US FDA Class II and EU Class IIa medical device that has received three regulatory clearances. The company is currently preparing a second-generation version of ClearUP (ClearUP Gen 2), which is covered by the same patents.

Tivic Health Systems was founded in 2016 and booked $1 million in sales for the 12 months ended June 30, 2021. It plans to list on the Nasdaq under the symbol TIVC. ThinkEquity is the sole bookrunner on the deal.

Read the source article.